Next Article in Journal
Fentanyl and Spiradoline Interactions in a Place-Conditioning Black-White Shuttle-Box
Previous Article in Journal
Drug Induced Hypersensitivity and the HLA Complex
Previous Article in Special Issue
EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment
Pharmaceuticals 2011, 4(1), 91-100; doi:10.3390/ph4010091

Molecular Therapies in Thyroid Cancer

 and *
Received: 2 November 2010 / Revised: 9 December 2010 / Accepted: 22 December 2010 / Published: 24 December 2010
(This article belongs to the Special Issue Targeted Therapy)
View Full-Text   |   Download PDF [53 KB, uploaded 27 December 2010]
Abstract: Thyroid cancer is a common diagnosis with greater than 34,000 cases per year in the United States. Early stage thyroid cancer is often managed with surgical intervention and radioactive iodine; however, for recurrent or metastatic disease, the treatment options, historically, have been limited to chemotherapy. Chemotherapy for metastatic thyroid cancer has been of limited efficacy. Encouragingly, molecular therapeutics have played a greater role in managing patients with advanced disease. These agents work primarily through disruption of tyrosine kinase pathways. This review will discuss the expanding role of molecular targets in managing patients with advanced thyroid cancer.
Keywords: advanced thyroid cancer; molecular therapy; tyrosine kinase inhibitors advanced thyroid cancer; molecular therapy; tyrosine kinase inhibitors
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Huyck, T.; Agulnik, M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals 2011, 4, 91-100.

AMA Style

Huyck T, Agulnik M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals. 2011; 4(1):91-100.

Chicago/Turabian Style

Huyck, Timothy; Agulnik, Mark. 2011. "Molecular Therapies in Thyroid Cancer." Pharmaceuticals 4, no. 1: 91-100.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert